Assembly Biosciences, Inc. Share Price & Technical Analysis
ASMB · $28.34 (+6.94%)
Healthcare / Biotechnology
$28.34
+6.94%
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
6% return in May, 11% avg return in past 3 year May month.
-11% return in 2026, 43% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | 17% | -5% | -4% | 6% | – | – | – | – | – | – | – | -11% |
| 25 | -12% | -7% | -27% | 19% | 23% | 28% | -2% | 39% | 6% | 22% | 22% | -10% | 100% |
| 24 | 13% | 13% | 2% | -6% | 16% | -10% | 7% | 16% | -8% | 12% | 0% | -9% | 47% |
| 23 | 29% | -24% | -38% | 23% | -5% | 22% | -3% | -8% | -10% | 2% | -23% | 17% | -19% |
| 22 | -20% | -18% | 34% | -16% | 10% | 10% | -2% | -11% | -13% | -1% | -22% | -1% | -51% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$481.86M
P/E ratio
379
52W high
$39.71
52W low
$13.70
Volume
8,93,900
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Assembly Biosciences, Inc. share price today?
- Assembly Biosciences, Inc. (ASMB) last traded around $28.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ASMB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ASMB. Download the app for real-time alerts.
- How can I analyze Assembly Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.